The FDA's decision to reconsider the treatment for a rare cancer comes after the unexpected rejection of Ebvallo.
The companies behind the drug have reportedly reached an agreement with the FDA to address the primary reasons for its initial denial.
This development may pave the way for further evaluation of Ebvallo, potentially benefiting patients in need of new treatment options.